Bli medlem
Bli medlem

Du är här


Orexo: Number of shares and votes in Orexo

Uppsala, Sweden - October 31, 2016 - The number of shares and votes in
Orexo AB has changed as a result of the exercise of warrants in
connection with the company's incentive programs and, as previous
announced, by issue and repurchase of class C shares.

Today, the last trading day of the month, there are in total
34,870,326 shares - whereof 34,535,326 are ordinary shares and
335,000 class C shares - and 34,568,826 votes in the company.

For further information, please contact:

Orexo AB (publ.)

Henrik Juuel, EVP and CFO Lena Wange, IR & Communications Manager
Tel: 018 780 88 00 Tel: 018 780 88 00
email: email:

About Orexo

Orexo is a specialty pharmaceutical company commercializing its
proprietary product Zubsolv® for treatment of opioid dependence in
the US. Zubsolv is an advanced formulation of buprenorphine and
naloxone using Orexo's unique knowledge and expertise in sublingual
drug delivery. R&D is focusing on reformulation of known substances
to new improved products that meet great unmet medical needs by using
its patented proprietary technologies. Orexo's share is listed on
Nasdaq Stockholm Exchange Mid Cap (STO: ORX) and is available as ADRs
on OTCQX (ORXOY) in the US. Orexo's global headquarters and R&D are
based in Uppsala, Sweden.

For more information about Orexo, please visit or follow
us on Twitter or LinkedIn. For further information about Zubsolv in
the US, please visit

The information was submitted for publication at 6:00pm CET, October
31, 2016


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.